Systematic review and meta-analysis of somatostatin analogues for the treatment of pancreatic fistula

British Journal of Surgery

Volumn 99, Issue 6, 2012, Pages 754-760

  Gans, S L ^a   Van Westreenen, H L ^b   Kiewiet, J J S ^a   Rauws, E A J ^a   Gouma, D J ^a   Boermeester, M A ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Department of Surgery ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; CYCLOPEPTIDE; DRUG DERIVATIVE; OCTREOTIDE; SOMATOSTATIN;

ADULT; AGED; HUMAN; META ANALYSIS; MIDDLE AGED; PANCREAS FISTULA; POSTOPERATIVE COMPLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME;

ADULT; AGED; HUMANS; MIDDLE AGED; OCTREOTIDE; PANCREATIC FISTULA; PEPTIDES, CYCLIC; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 84860498529     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.8709     Document Type: Review

References (29)

1. Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J, et al.,; International Study Group on Pancreatic Fistula Definition. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 2005; 138: 8-13.
2. Li-Ling J, Irving M,. Somatostatin and octreotide in the prevention of postoperative pancreatic complications and the treatment of enterocutaneous pancreatic fistulas: a systematic review of randomized controlled trials. Br J Surg 2001; 88: 190-199.
3. Bassi C, Butturini G, Molinari E, Mascetta G, Salvia R, Falconi M, et al., Pancreatic fistula rate after pancreatic resection. The importance of definitions. Dig Surg 2004; 21: 54-59.
4. Zeng Q, Zhang Q, Han S, Yu Z, Zheng M, Zhou M, et al., Efficacy of somatostatin and its analogues in prevention of postoperative complications after pancreaticoduodenectomy: a meta-analysis of randomized controlled trials. Pancreas 2008; 36: 18-25.
5. Ramos-De la Medina A, Sarr MG,. Somatostatin analogues in the prevention of pancreas-related complications after pancreatic resection. J Hepatobiliary Pancreat Surg 2006; 13: 190-193.
6. Leandros E, Antonakis PT, Albanopoulos K, Dervenis C, Konstadoulakis MM,. Somatostatin versus octreotide in the treatment of patients with gastrointestinal and pancreatic fistulas. Can J Gastroenterol 2004; 18: 303-306.
7. Boerma D, Rauws EA, van Gulik TM, Huibregtse K, Obertop H, Gouma DJ,. Endoscopic stent placement for pancreaticocutaneous fistula after surgical drainage of the pancreas. Br J Surg 2000; 87: 1506-1509.
8. Gayral F, Campion JP, Regimbeau JM, Blumberg J, Maisonobe P, Topart P, et al.,; Lanreotide Digestive Fistula. Randomized, placebo-controlled, double-blind study of the efficacy of lanreotide 30 mg PR in the treatment of pancreatic and enterocutaneous fistulae. Ann Surg 2009; 250: 872-877.
9. Goh BK, Tan YM, Chung YF, Cheow PC, Ong HS, Chan WH, et al., Critical appraisal of 232 consecutive distal pancreatectomies with emphasis on risk factors, outcome, and management of the postoperative pancreatic fistula: a 21-year experience at a single institution. Arch Surg 2008; 143: 956-965.
10. Klek S, Sierzega M, Turczynowski L, Szybinski P, Szczepanek K, Kulig J,. Enteral and parenteral nutrition in the conservative treatment of pancreatic fistula: a randomized clinical trial. Gastroenterology 2011; 141: 157-163, 163.e1.
11. Ramacciato G, Mercantini P, Petrucciani N, Nigri GR, Kazemi A, Muroni M, et al., Risk factors of pancreatic fistula after pancreaticoduodenectomy: a collective review. Am Surg 2011; 77: 257-269.
12. Hesse U, Ysebaert D, de Hemptinne B,. Role of somatostatin-14 and its analogues in the management of gastrointestinal fistulae: clinical data. Gut 2001; 49 (Suppl 4): iv11-iv21.
13. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al., Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
14. Ziegler A, Antes G, König IR,. [Preferred reporting items of systematic review and meta-analyses: the PRISMA statement.] Dtsch Med Wochenschr 2011; 136: e9-e15.
15. Gerardo Pérez D, Bernardo Acosta M,. [Gastrointestinal fistulas. Treatment with a somatostatin analogue (SMS 201-995).] G E N 1994; 48: 209-218.
16. Scott NA, Finnegan S, Irving MH,. Octreotide and gastrointestinal fistulae. Digestion 1990; 45 (Suppl 1): 66-70.
17. Torres AJ, Landa JI, Moreno-Azcoita M, Arguello JM, Silecchia G, Castro J, et al., Somatostatin in the management of gastrointestinal fistulas. A multicenter trial. Arch Surg 1992; 127: 97-99.
18. Scott NA, Finnegan S, Irving MH,. Octreotide and postoperative enterocutaneous fistulae: a controlled prospective study. Acta Gastroenterol Belg 1993; 56: 266-270.
19. Sancho JJ, di Costanzo J, Nubiola P, Larrad A, Beguiristain A, Roqueta F, et al., Randomized double-blind placebo-controlled trial of early octreotide in patients with postoperative enterocutaneous fistula. Br J Surg 1995; 82: 638-641.
20. Jamil M, Ahmed U, Sobia H,. Role of somatostatin analogues in the management of enterocutaneous fistulae. J Coll Physicians Surg Pak 2004; 14: 237-240.
21. Bakker OJ, van Baal MC, van Santvoort HC, Besselink MG, Poley JW, Heisterkamp J, et al.,; Dutch Pancreatitis Study Group. Endoscopic transpapillary stenting or conservative treatment for pancreatic fistulas in necrotizing pancreatitis: multicenter series and literature review. Ann Surg 2011; 253: 961-967.
22. Cicek B, Parlak E, Oguz D, Disibeyaz S, Koksal AS, Sahin B,. Endoscopic treatment of pancreatic fistulas. Surg Endosc 2006; 20: 1706-1712.
23. Costamagna G, Mutignani M, Ingrosso M, Vamvakousis V, Alevras P, Manta R, et al., Endoscopic treatment of postsurgical external pancreatic fistulas. Endoscopy 2001; 33: 317-322.
24. Howard TJ, Stonerock CE, Sarkar J, Lehman GA, Sherman S, Wiebke EA, et al., Contemporary treatment strategies for external pancreatic fistulas. Surgery 1998; 124: 627-632.
25. Kozarek RA, Ball TJ, Patterson DJ, Raltz SL, Traverso LW, Ryan JA, et al., Transpapillary stenting for pancreaticocutaneous fistulas. J Gastrointest Surg 1997; 1: 357-361.
26. Telford JJ, Farrell JJ, Saltzman JR, Shields SJ, Banks PA, Lichtenstein DR, et al., Pancreatic stent placement for duct disruption. Gastrointest Endosc 2002; 56: 18-24.
27. Varadarajulu S, Noone TC, Tutuian R, Hawes RH, Cotton PB,. Predictors of outcome in pancreatic duct disruption managed by endoscopic transpapillary stent placement. Gastrointest Endosc 2005; 61: 568-575.
28. Cooper ST, Slivka A,. Incidence, risk factors, and prevention of post-ERCP pancreatitis. Gastroenterol Clin North Am 2007; 36: 259-276, vii-viii.
29. Testoni PA, Mariani A, Giussani A, Vailati C, Masci E, Macarri G, et al.,; SEIFRED Group. Risk factors for post-ERCP pancreatitis in high- and low-volume centers and among expert and non-expert operators: a prospective multicenter study. Am J Gastroenterol 2010; 105: 1753-1761.